Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study

Long-acting bronchodilators including muscarinic antagonists are central to the management of patients with COPD. The Glycopyrrolate Effect on syMptoms and lung function (GEM2) study assessed the efficacy and safety of twice-daily glycopyrrolate 15.6 μg in patients with moderate-to-severe airflow li...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Chronic Obstr Pulm Dis
Autori principali: Kerwin, Edward, Siler, Thomas M., Korenblat, Phillip, White, Alexander, Eckert, Joerg H., Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Natura: Artigo
Lingua:Inglês
Pubblicazione: COPD Foundation Inc 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559157/
https://ncbi.nlm.nih.gov/pubmed/28848879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.3.2.2015.0157
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi